LobbyingCorewell Health lobbying by quarter
Corewell Health's latest lobbying report covers Q2 2026, at $210K. The four quarters Q4 2025–Q3 2026 total $570K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Corewell Health
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $570K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $220K | 1 |
| Q1 2023 | $130K | 1 |
| Q2 2023 | $160K | 1 |
| Q3 2023 | $140K | 1 |
| Q4 2023 | $130K | 1 |
| Q1 2024 | $180K | 1 |
| Q2 2024 | $160K | 1 |
| Q3 2024 | $140K | 1 |
| Q4 2024 | $140K | 1 |
| Q1 2025 | $190K | 1 |
| Q2 2025 | $270K | 1 |
| Q3 2025 | $190K | 1 |
| Q4 2025 | $180K | 1 |
| Q1 2026 | $180K | 1 |
| Q2 2026 | $210K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$665.1K · 15 reports
- Medicare and Medicaid$665.1K · 15 reports
- Labor, antitrust and workplace$490.1K · 13 reports
- Pharmacy$490.1K · 13 reports
- Budget and appropriations$114.1K · 3 reports
- Tariffs$102.1K · 3 reports
- Immigration$57.1K · 2 reports
- Education$36K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Centers For Medicare and Medicaid Services (CMS)5 reports
- Executive Office of the President (EOP)2 reports
- Health & Human Services, Dept of (HHS)2 reports
- Drug Enforcement Administration (DEA)1 reports
- Education, Dept of1 reports
- Health Resources & Services Administration (HRSA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseCorewell Health | $2.6M | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| KRISTINA KO | Chief Government Affairs Officer | Q4 2025 |
| PHILIP D YEITER | Senior Director, Government Relations | Q4 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/15for Q2 | In-house | $210K |
| 04/16for Q1 | In-house | $180K |
| 01/15for Q4 2025 | In-house | $180K |
| 25/10/16for Q3 2025 | In-house | $190K |
| 25/07/17for Q2 2025 | In-house | $270K |
| 25/04/18for Q1 2025 | In-house | $190K |
| 25/01/16for Q4 2024 | In-house | $140K |
| 24/10/15for Q3 2024 | In-house | $140K |
| 24/07/19for Q2 2024 | In-house | $160K |
| 24/04/18for Q1 2024 | In-house | $180K |
| 24/01/18for Q4 2023 | In-house | $130K |
| 23/10/19for Q3 2023 | In-house | $140K |
| 23/07/21for Q2 2023 | In-house | $160K |
| 23/07/20for Q2 2023 | In-house | $160K |
| 23/07/20for Q2 2023 | In-house | $160K |
| 23/04/20for Q1 2023 | In-house | $130K |
| 23/01/20for Q4 2022 | In-house | $220K |